Biological bases for a possible effect of cannabidiol in Parkinson’s disease

Current pharmacotherapy of Parkinson’s disease (PD) is palliative and unable to modify the progression of neurodegeneration. Treatments that can improve patients’ quality of life with fewer side effects are needed, but not yet available. Cannabidiol (CBD), the major non-psychotomimetic constituent o...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferreira-Junior, Nilson C., Campos, Alline C., Guimarães, Francisco S., Del-Bel, Elaine, Zimmermann, Patrícia M. da R., Brum, Liberato, Hallak, Jaime E., Crippa, José A., Zuardi, Antonio W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Associação Brasileira de Psiquiatria 2019
Materias:
Special Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115443/
https://www.ncbi.nlm.nih.gov/pubmed/31314869
http://dx.doi.org/10.1590/1516-4446-2019-0460

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115443/
https://www.ncbi.nlm.nih.gov/pubmed/31314869
http://dx.doi.org/10.1590/1516-4446-2019-0460

Ejemplares similares